Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

591
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
591
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

607
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
607
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

981
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
981
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.4K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilizing Life's Crucial 9 for Rheumatoid Arthritis Risk Prediction: A Machine Learning Approach Based on NHANES Data.

Food science & nutrition·2026
Same author

Multi-faceted characterization of the gut microbiome and metabolome in patients with primary Sjögren syndrome.

Cell reports. Medicine·2026
Same author

From pathogenesis to precision medicine in systemic lupus erythematosus: Emerging biomarkers and targeted interventions.

iScience·2026
Same author

Kaempferol suppresses fibroblast-like synoviocyte proliferation in rheumatoid arthritis by targeting glutamate-cysteine ligase modifier subunit to inhibit ferroptosis resistance.

Bone & joint research·2026
Same author

FOXC1-ATP7A Axis Activates PI3K/AKT Signaling to Suppress Cuproptosis and Drive Fibroblast Pathogenesis in Rheumatoid Arthritis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Liquid chromatography-tandem mass spectrometry technology revealed differences in serum metabolites between rheumatoid arthritis patients in different seasons.

Frontiers in immunology·2026

Related Experiment Video

Updated: Mar 15, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
08:02

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice

Published on: February 18, 2015

10.4K

Stomatitis Powder Ameliorates Oral Ulcer Symptoms by Increasing Col11a1 Expression.

Mianjie Wang1, Yulin Wang2, Wukai Ma3

  • 1Department of Stomatology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, 550001, China.

Combinatorial Chemistry & High Throughput Screening
|March 14, 2026
PubMed
Summary

Stomatitis Powder effectively treats oral ulcers by modulating key genes like Col11a1, reducing fibrosis, and accelerating wound healing. This study elucidates its pharmacological mechanisms using RNA sequencing and bioinformatics.

Keywords:
Col11a1RNA sequencingStomatitis powderanti-inflammatory agents.fibrosisoral ulcer

More Related Videos

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
06:06

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Published on: May 9, 2022

3.3K
Author Spotlight: Enhancing Dental Pulp Research with Improved Mouse Models
05:16

Author Spotlight: Enhancing Dental Pulp Research with Improved Mouse Models

Published on: October 27, 2023

2.0K

Related Experiment Videos

Last Updated: Mar 15, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
08:02

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice

Published on: February 18, 2015

10.4K
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
06:06

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Published on: May 9, 2022

3.3K
Author Spotlight: Enhancing Dental Pulp Research with Improved Mouse Models
05:16

Author Spotlight: Enhancing Dental Pulp Research with Improved Mouse Models

Published on: October 27, 2023

2.0K

Area of Science:

  • Pharmacology
  • Genomics
  • Traditional Chinese Medicine

Background:

  • Stomatitis Powder is a Traditional Chinese Medicine (TCM) used for oral ulcers (OU).
  • Its therapeutic mechanisms are not well understood.
  • This study aims to clarify the pharmacological basis of Stomatitis Powder for OU treatment.

Purpose of the Study:

  • To investigate the pharmacological mechanisms of Stomatitis Powder in treating oral ulcers.
  • To identify key genes and pathways involved in the therapeutic effects of Stomatitis Powder.
  • To provide a scientific rationale for the clinical application of Stomatitis Powder.

Main Methods:

  • RNA sequencing was performed on oral mucosal tissues before and after Stomatitis Powder treatment.
  • Differentially Expressed Genes (DEGs) were identified and intersected with pain-related genes.
  • Protein-Protein Interaction (PPI) network analysis was used to identify key genes, followed by validation in an oral ulcer rat model.

Main Results:

  • 443 DEGs were identified, yielding 20 candidate genes after intersecting with pain-related genes.
  • Four key genes (Col11a1, Col5a1, Enpp1, Pth1r) were identified through PPI network analysis.
  • Stomatitis Powder upregulated Col11a1, alleviated fibrosis, and accelerated wound healing in an oral ulcer rat model.

Conclusions:

  • The study identified Col11a1 as a key gene in the therapeutic effects of Stomatitis Powder on oral ulcers.
  • Modern pharmacological techniques confirm the efficacy of Stomatitis Powder in treating oral ulcers.
  • These findings provide a scientific basis for the use of Stomatitis Powder in clinical practice.